What drugs does SHUANGCHENG make?

SHUANGCHENG has 6 FDA-approved drugs.

What therapeutic areas does SHUANGCHENG focus on?

SHUANGCHENG focuses primarily on Cardiovascular.

← Back

Data updated: Jun 28, 2026

SHUANGCHENG

Generics

Cardiovascular

SHUANGCHENG is a generic drug manufacturer focused on Cardiovascular.

2019

Since

Drugs

Trials

New Drugs (2yr)

SHUANGCHENG's Key Drugs

SHUANGCHENG's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

SHUANGCHENG's Recent FDA Approvals

SHUANGCHENG secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

BORTEZOMIB NDA

2024-08-26

bortezomib

1 INDICATIONS AND USAGE Bortezomib for injection is a proteasome inhibitor indicated for: • treatment of adult patients with multiple myeloma ( 1.1 ) • treatment of adult patients with mantle cell lymphoma ( 1.2 ) 1.1 Multiple Myeloma Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma. 1.2 Mantle Cell Lymphoma Bortezomib for injection is indicated for the treatment of adult patients with mantle cell lymphoma.

SHUANGCHENG's Therapeutic Areas

SHUANGCHENG's approved drugs and pipeline span 1 therapeutic area, led by Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 100%

2 drugs

SHUANGCHENG's Top Competitors

SHUANGCHENG's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.